Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Tonsils are lymphatic organs carrying out functions of humoral and cellular immunity. They form a local immunologic barrier; they are also involved in general immunologic defence mechanisms. Tonsillectomy or the destruction of tonsils by infections does not reduce the immunoglobulin concentration and antibody titres in peripheral blood. Only the local formation of IgA antibodies against poliomyelitis antigen seems to be impaired at least for a short time. The clinical relevance of this finding is unknown. Signs of defects in immunosurveillance, which were found in some study groups resulting from an increase of the morbidity rates of Hodgkin's disease and thyroid carcinoma, must be considered seriously although there is no statistic evidence for an increase of tumor frequency after tonsillectomy. The indication for tonsillectomy must be decided on clinical findings. Signs for a reduction of local antibody synthesis or for a possible diminuation of immunosurveillance should serve to critical indication.
HNO 1975 Sep
PMID:[Tonsils and immunology (author's transl)]. 110 43

Malignant non-Hodgkin's lymphomas are a heterogeneous group of neoplasms with different natural histories and prognoses. Often the patient is first seen by the ENT-specialist with cervical lymphadenopathy as the first complaint. In Germany the histological Kiel-classification is most often used. This is based on the normal structures of the lymphatic tissue as the basis. Therapy is quite different for the various lymphomas depending on histology and stage of disease. Chemotherapy of varying intensity, radiotherapy, or both may be used. Prognosis is less favourable than in Hodgkin's disease but some subgroups have a chance of cure even in advanced stages and others run a natural course over several years without treatment.
HNO 1985 Nov
PMID:[Malignant non-Hodgkin lymphomas--a review]. 407 87

Lennert's classification of non-Hodgkin-lymphomas is introduced including a brief explanation of certain ENT aspects. The problems of the prognosis, therapy and a staging have an increasing interest for the ENT physician. Particular clinical pictures of non-Hodgkin's lymphomas in the head and neck region are described.
HNO 1983 Aug
PMID:[Classification and evaluation of non-Hodgkin lymphomas and their manifestations in the ENT area]. 662 64

The natural history of malignant lymphomas of the oropharynx and their response to treatment are described by evaluating the course of 41 patients, who after histological verification underwent radiotherapy in the Radiological Clinic of Kiel University between 1965 and 1979. The analysis of the malignant non-Hodgkin lymphomas according to the "Kiel classification" reveals a clear predominance of the germinal center tumors and the high grade malignancies. The long-term results of treatment show a good prognosis for clinical stages I-II1 (two adjacent lymph node or extranodal regions involved above the diaphragm, "Ann Arbor"-classification modified by Musshoff) with a 85% probability of both survival and freedom of disease. For clinical stages II2-IV long-term actuarial survival and disease free survival were lowered to 51% and 23%. Whereas in 93% a complete tumor regression could be achieved by the primary treatment, one third of these patients developed a recurrence of the disease, mainly caused by incomplete therapy, such as missing the "extended field" radiotherapy or a necessary chemotherapy because of old age, myelodepression or simply refusion of further treatment. According to the results of this study chemotherapy seems to be necessary from clinical stage II2 on (two distant lymph node or extranodal regions or three or more regions located anywhere involved above the diaphragm). Finally a refined locoregional irradiation technique for malignant lymphomas of the oropharynx is described: fast electrons and cobalt rays in daily alternation for the posterior cervical lymphnodes. Last not least we present the unusual treatment schemes of the "Kiel Lymphoma Study Group" for malignant non-Hodgkin-Lymphomas of different histologies and stages.
HNO 1981 Sep
PMID:[Treatment of malignant lymphomas of the oropharynx (author's transl)]. 731 49

Lymphoreticular neoplasms of the larynx are rare and comprise a heterogeneous group of tumors. A systematic survey of the literature and autoptic evaluation of the larynx in a relatively small number of patients with systemic lymphoreticular malignancies yielded the following findings: Primary tumors of the larynx must be clearly distinguished from laryngeal involvement by systemic or leukemic infiltrations. By far the most common primary hemopoietic tumors of the larynx are extramedullary plasmacytoma (about 90 cases published) and non-Hodgkin's lymphoma (NHL; about 65 cases published). Primary Hodgkin's disease, granulocytic sarcoma and mast cell sarcoma are extremely rare at this site. Plasmacytoma and NHL both preferentially involve the supraglottis. The subglottis is infrequently affected. Laryngeal plasmacytoma and NHL usually present clinically as localized stage IE and IIE tumors that exhibit no significant tendency to recur or generalize. The therapy of choice is local irradiation while chemotherapy should be reserved for recurrent or progressive disease. Prognosis is favourable in most cases of primary laryngeal plasmacytoma and NHL. Secondary involvement of the larynx by systemic lesions or leukemic infiltrations is usually associated with a very poor prognosis. The prognosis of patients with laryngeal involvement in acute or chronic myeloid leukemia is always poor. Although the histopathological diagnoses given in many case reports are often difficult to compare because of differences in terminology, there seems to be a marked preponderance of B-cell tumors of high-grade malignancy (centroblastic or immunoblastic lymphoma in the Kiel classification of NHL) that probably represents lymphomas originating from mucosa-associated lymphoid tissue (MALT).(ABSTRACT TRUNCATED AT 250 WORDS)
HNO 1994 Jul
PMID:[The larynx in lymphoproliferative and myeloproliferative diseases. Part II: Laryngeal autopsy findings and discussion]. 792 29

Lymphoreticular neoplasms of the larynx are rare and comprise a heterogeneous group of tumors. A systematic survey of the literature and autoptic evaluation of the larynx in a relatively small number of patients with systemic lymphoreticular malignancies yielded the following findings: Primary tumors of the larynx must be clearly distinguished from laryngeal involvement by systemic or leukemic infiltrations. By far the most common primary hemopoietic tumors of the larynx are extramedullary plasmacytoma (about 90 cases published) and non-Hodgkin's lymphoma (NHL; about 65 cases published). Primary Hodgkin's disease, granulocytic sarcoma and mast cell sarcoma are extremely rare at this site. Plasmacytoma and NHL both preferentially involve the supraglottis. The subglottis is infrequently affected. Laryngeal plasmacytoma and NHL usually present clinically as localized stage IE and IIE tumors that exhibit no significant tendency to recur or generalize. The therapy of choice is local irradiation while chemotherapy should be reserved for recurrent or progressive disease. Prognosis is favorable in most cases of primary laryngeal plasmacytoma and NHL. Secondary involvement of the larynx by systemic lesions or leukemic infiltrations is usually associated with a very poor prognosis. The prognosis of patients with laryngeal involvement in acute or chronic myeloid leukemia is always poor. Although the histopathological diagnoses given in many case reports are often difficult to compare because of differences in terminology, there seems to be a marked preponderance of B-cell tumors of high-grade malignancy (centroblastic or immunoblastic lymphoma in the Kiel classification of NHL) that probably represents lymphomas originating from mucosa-associated lymphoid tissue (MALT).(ABSTRACT TRUNCATED AT 250 WORDS)
HNO 1994 Jun
PMID:[The larynx in lymphoproliferative and myeloproliferative diseases. I: An overview with special reference to primary laryngeal malignant lymphomas and plasmacytomas]. 807 Oct 93

The life span of HIV-infected patients has increased because of anti-retroviral therapy and improved means for treating opportunistic infections. However, HIV infection and subsequent immunosuppression result in an increased risk of high-grade B-cell lymphomas. The purpose of this study was to determine the incidence, localization, clinical features, therapy and survival time of patients with HIV-related lymphomas of the head and neck. Between 1988 and 1995, 280 HIV-infected patients presented with otolaryngologic symptoms. Seventy-two (25.7%) were found to have a neoplastic disease. Fifty-six of these patients (20%) were diagnosed as having Kaposi's sarcoma and 12 (4.3%) had lymphomas. According to the Kiel classification, lymphomas were subdivided into Hodgkin's disease (2 cases) and B-cell lymphomas of high-grade malignancy (10 cases). These latter cases were centroblastic (n = 4), Burkitt's type (n = 4), anaplastic large cell (n = 1) and not classifiable (n = 1). All patients with HIV-related non-Hodgkin's lymphomas (NHL) were men and 8 were homosexuals. The mean age was 36.1 years. In addition to 7 nodal locations, high-grade B-cell lymphomas were found in the oropharynx (n = 2) and palate (n = 1). Four patients underwent chemotherapy, 1 patient underwent radiation therapy and 2 were treated with both methods. Two patients did not receive any treatment and 1 patient underwent laser therapy. The survival time depended on the previous diagnosis of AIDS, the patients' immune status and the karnofsky index. In 2 patients the lymphoma led to the diagnosis of HIV infection. Our findings show that any solitary or enlarging tumors or ulcerating lesions in the head and neck region of HIV patients must be examined histologically to exclude HIV-NHL. We also recommend that young patients with high-grade B-cell lymphomas should undergo HIV screening.
HNO 1997 Jan
PMID:[HIV-associated non-Hodgkin's lymphomas (HIV-NHL) in the area of the head-neck]. 913 94

Nitric oxide (NO) synthase (NOS) inhibition with N(omega)-nitro-L-arginine (L-NNA) produces L-NNA hypertensive rats (LHR), which exhibit increased sensitivity to voltage-dependent Ca(2+) channel-mediated vasoconstriction. We hypothesized that enhanced contractile responsiveness after NOS inhibition is mediated by depolarization of membrane potential (E(m)) through attenuated K(+) channel conductance. E(m) measurements demonstrated that LHR vascular smooth muscle cells (VSMCs) are depolarized in open, nonpressurized (-44.5 +/- 1.0 mV in control vs. -36.8 +/- 0.8 mV in LHR) and pressurized mesenteric artery segments (-41.8 +/- 1.0 mV in control vs. -32.6 +/- 1.4 mV in LHR). Endothelium removal or exogenous L-NNA depolarized control VSMCs but not LHR VSMCs. Superfused L-arginine hyperpolarized VSMCs from both the control and LHR groups and reversed L-NNA-induced depolarization (-44.5 +/- 1.0 vs. -45.8 +/- 2.1 mV). A Ca(2+)-activated K(+) channel agonist, NS-1619 (10 microM), hyperpolarized both groups of arteries to a similar extent (from -50.8 +/- 1.0 to -62.5 +/- 1.2 mV in control and from -43.7 +/- 1.1 to -55.6 +/- 1.2 mV in LHR), although E(m) was still different in the presence of NS-1619. In addition, superfused iberiotoxin (50 nM) depolarized both groups similarly. Increasing the extracellular K(+) concentration from 1.2 to 45 mM depolarized E(m), as predicted by the Goldman-Hodgkin-Katz equation. These data support the hypothesis that loss of NO activation of K(+) channels contributes to VSMC depolarization in L-NNA-induced hypertension without a change in the number of functional large conductance Ca(2+)-activated K(+) channels.
 ...
PMID:Vascular smooth muscle cell membrane depolarization after NOS inhibition hypertension. 1195 27

1.-- As shown in a parallel study the magnitude of depolarization induced in human saphenous vein by raising external potassium ([K(+)](e)) falls markedly below the theoretical values predicted by the Goldman-Hodgkin-Katz equations. This anomaly prompted us to re-examine the relaxant actions of L-type (nifedipine) and T-type (mibefradil) Ca(2+) channel antagonists, and relaxant and electrophysiological effects of the K(+) channel opener, pinacidil, on saphenous veins contracted by the elevation of [K(+)](e). 2.-- Nifedipine produced concentration-dependent relaxations in tissues contracted at various high [K(+)](e). In tissues contracted with 20 mm [K(+)](e), the pIC(50) for nifedipine was significantly (8.20 +/- 0.05; n = 6; mean +/- SEM; P < 0.05) greater than in tissues contracted with > or =40 mm [K(+)](e). 3.-- Tissues contracted with 20 mm [K(+)](e) also relaxed in response to mibefradil (pIC(50) = 6.1 +/- 0.14) and pinacidil (pIC(50) = 6.45 +/- 0.08), the latter being almost completely reversed (93.4 +/- 9.9%) by addition of glibenclamide (10 microm). 4.-- The resting E(m) of smooth muscle cells of saphenous vein was -77.0 +/- 0.7 mV (n = 52), and 20 mm [K(+)](e) produced a modest but significant depolarization to -73.0 +/- 0.7 mV (n = 52). Incubation with pinacidil plus 20 mm [K(+)](e) resulted in a significant hyperpolarization of the E(m) to -82 +/- 0.6 mV (n = 52). 5.-- N(omega)-nitro-L-arginine methyl ester did not impede the relaxant responses of nifedipine, mibefradil or pinacidil. 6.-- In conclusion, the relaxant effects of nifedipine and pinacidil (i) occurred at an E(m) distinctly below the presumed threshold for the opening of the classic (Ca(V)1.3alpha(1)) L-type Ca(2+) channels, and (ii) did not depend on generation of nitric oxide.
 ...
PMID:Relaxant responses to calcium channel antagonists and potassium channel opener in human saphenous vein. 1637 Oct 61

This study investigated changing levels of serum oxidant/antioxidant with chemotherapy and their relation to treatment in 34 Hodgkin's lymphoma patients. The patient population consisted of 19 males and 15 females. Mean age was 30.41 +/- 12.08 years. All patients received the adriamycin, bleomycin, vincristine and dexamethasone (ABVD) treatment protocol. Blood samples were taken before treatment, and on days 1 and 7 during treatment for measurement of superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), catalase (CAT), malondialdehyde (MDA), nitric oxide (NO) and enzyme activities. After ABVD treatment, mean free radical levels were increased and antioxidant levels were significantly decreased in the serum. ABVD treatment results in an increase of free radical levels and a decrease of antioxidant levels in the serum of patients with Hodgkin's lymphoma.
 ...
PMID:Oxidant/antioxidant parameters and their relationship with chemotherapy in Hodgkin's lymphoma. 1637 87


1 2 3 Next >>